Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia

This publication has 15 references indexed in Scilit:

• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  Journal of Clinical Oncology, 1998
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs
  Cancer Biotherapy & Radiopharmaceuticals, 1997
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
  Journal of Clinical Oncology, 1996
• A phase II study of subcutaneous recombinant human lnterleukjn-4 in metastatic renal cell carcinoma
  Cancer, 1995
• Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma
  Journal of Immunotherapy, 1994
• Possible Myocardial Toxicity Associated with Interleukin-4 Therapy
  Journal of Immunotherapy, 1993
• Sensitivity of Drug-Resistant Human Ovarian Tumor Cell Lines to Combined Effects of Tumor Necrosis Factor (TNF-α) and Doxorubicin: Failure of the Combination to Modulate the MDR Phenotype
  Gynecologic Oncology, 1993
• Isolated human follicular dendritic cells display a unique antigenic phenotype.
  The Journal of Experimental Medicine, 1989
• Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
  Blood, 1984
• Characterization of a human B lymphocyte-specific antigen.
  The Journal of Immunology, 1980